In a nationwide retrospective cohort study, HCC patients underwent either TACE with PD-1/PD-L1 inhibitors plus MTT (TKI or anti-VEGF monoclonal antibody) or TACE monotherapy. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.